The FDA has delayed its decision on AstraZeneca’s oral SERD camizestrant after an advisory committee voted against approval for a first-line breast cancer indication. AstraZeneca said the extra time is intended to allow the agency to review additional analyses submitted as part of the SERENA-6 dataset. The advisory panel raised concerns around the study design, including the trial’s approach to switching patients to camizestrant earlier than typical progression-based decision points. External reviewers also questioned the completeness of survival evidence and the clarity of quality-of-life findings. For investors and clinicians, the delay keeps attention on how the FDA will weigh progression-risk reduction versus survival endpoints and patient-reported outcomes. AstraZeneca is proposing to combine camizestrant with the AKT inhibitor Truqap for ESR1-mutant, HER2-negative, HR-positive advanced disease, with the next FDA milestone determining whether the oral SERD can move forward in the U.S.